Key Events This Week
2 Feb: Strong gap up opens week at Rs.434.60 (+5.65%)
3 Feb: Intraday high of Rs.464.35, closes at Rs.438.15 (+0.82%)
5 Feb: Valuation concerns emerge as stock dips 3.63% to Rs.432.00
6 Feb: Week closes at Rs.425.05 (-1.61%) amid cautious sentiment

Vimta Labs Ltd Valuation Shifts Signal Price Attractiveness Challenges
2026-02-05 08:00:12Vimta Labs Ltd, a prominent player in the healthcare services sector, has witnessed a notable shift in its valuation parameters, moving from fair to expensive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a diminished price attractiveness despite the company’s robust operational performance and long-term returns that have outpaced the broader market.
Read full news article
Vimta Labs Ltd Opens with Strong Gap Up, Reflecting Positive Market Sentiment
2026-02-03 11:06:02Vimta Labs Ltd witnessed a significant gap up at market open on 3 Feb 2026, surging by 6.85% to touch an intraday high of Rs 464.35. This strong start reflects positive sentiment within the healthcare services sector despite the stock’s recent underperformance relative to broader benchmarks.
Read full news articleVimta Labs Falls 19.71%: 6 Key Factors Driving the Sharp Weekly Decline
2026-02-01 14:01:16
Key Events This Week
27 Jan: Death Cross formation signals bearish trend
27 Jan: Technical momentum shifts amid market volatility
28 Jan: Intraday low hit amid price pressure
28 Jan: Q3 FY26 results reveal strong profit surge but valuation concerns
29 Jan: Intraday low and continued price pressure
29 Jan: Flat quarterly performance amid margin pressures reported

Vimta Labs Ltd Hits Intraday High with 9.24% Surge on 1 Feb 2026
2026-02-01 11:31:22Vimta Labs Ltd recorded a robust intraday performance on 1 Feb 2026, surging 9.24% to touch a day’s high of Rs 462.4, marking a significant rebound after five consecutive days of decline. The stock outperformed its healthcare services sector peers and the broader market, reflecting heightened trading activity and volatility.
Read full news article
Vimta Labs Ltd is Rated Sell
2026-01-30 10:10:03Vimta Labs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 16 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 January 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Vimta Labs Ltd Hits Intraday Low Amid Price Pressure on 29 Jan 2026
2026-01-29 14:17:23Vimta Labs Ltd experienced a significant intraday decline, touching a low of Rs 423.55, reflecting a sharp 7.43% drop amid persistent selling pressure and subdued market sentiment. The stock underperformed its sector and broader indices, continuing a multi-day downward trend.
Read full news article
Vimta Labs Ltd Reports Flat Quarterly Performance Amid Margin Pressures
2026-01-29 08:00:08Vimta Labs Ltd, a key player in the Healthcare Services sector, has reported a flat financial performance for the quarter ended December 2025, marking a significant shift from its previously positive growth trajectory. Despite record-high cash reserves and PBDIT, the company’s earnings per share have declined to their lowest quarterly level, prompting a downgrade in its Mojo Grade from Hold to Sell.
Read full news articleAre Vimta Labs Ltd latest results good or bad?
2026-01-28 19:15:53Vimta Labs Ltd's latest financial results for Q3 FY26 reveal a significant year-on-year growth in consolidated net profit, which reached ₹21.50 crores, reflecting a notable increase compared to the previous year. Revenue for the same quarter was reported at ₹89.92 crores, marking a robust year-on-year growth of 20.57%. The operating margin, excluding other income, improved to 36.79%, indicating effective cost management and operational efficiency. The company demonstrated strong operational performance, with the operating profit before depreciation, interest, and tax rising to ₹33.08 crores, showcasing a substantial margin expansion of 479 basis points from the prior year. This operational leverage is further underscored by the return on equity, which stood at 17.82% for the latest financial year, highlighting effective capital utilization. However, the standalone results for the quarter ended December 20...
Read full news articleAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript
03-Feb-2026 | Source : BSETranscript - Q3 FY 2025-26 - Investor Call Held on 28th January 2026.
Announcement under Regulation 30 (LODR)-Newspaper Publication
29-Jan-2026 | Source : BSENewspaper Publication - Unaudited Financial Results of Q3 FY 2025-26.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28-Jan-2026 | Source : BSEQ3 FY 2025-26 Press Release - Unaudited Financial Results - 31st December 2025.
Corporate Actions
No Upcoming Board Meetings
Vimta Labs Ltd has declared 100% dividend, ex-date: 30 May 25
Vimta Labs Ltd has announced 2:10 stock split, ex-date: 24 Feb 06
Vimta Labs Ltd has announced 1:1 bonus issue, ex-date: 13 Jun 25
No Rights history available






